20 articles
Stanford researchers used smartwatches and blood tests to monitor dangerous side effects during cutting-edge CAR-T cancer treatment.
New liquid biopsy technique identifies molecular residual disease in colorectal cancer patients to guide personalized treatment decisions.
A Swiss feasibility trial tests digital mindfulness-based cancer recovery, tracking psychosocial outcomes, medication use, and biological markers.
A large retrospective study tests whether AI-enhanced ECGs can flag cardiac risk before chemotherapy, potentially protecting cancer patients from heart damage.
Researchers explored whether cancer-derived cell-free DNA and telomere maintenance mutations could serve as early warning biomarkers in soft tissue sarcoma patients.
A completed NCI trial evaluated advanced imaging and breast duct lavage in women with BRCA1/BRCA2 mutations to improve early cancer detection.
A phase 1/2 trial combined mocetinostat and durvalumab in 83 patients with advanced solid tumors and NSCLC.
New diagnostic chip analyzes blood exosomes to detect early lung spread of bone cancer, potentially improving treatment outcomes.
New study shows how analyzing fluid from lungs can detect cancer mutations and guide personalized treatment decisions.
Modified immune cells targeting GD2 protein demonstrated safety in treating aggressive childhood cancers like neuroblastoma and osteosarcoma.
A Columbia University trial tested a digital care service to improve immunotherapy outcomes and reduce healthcare burden for minority lung cancer patients.
Genetically modified immune cells target blood cancer that stopped responding to standard treatments in 28-patient trial.
Eight-week study of weekday-only intermittent fasting in older breast cancer survivors with overweight demonstrates feasibility.
GSK's Phase 1/2 trial tests belantamab mafodotin paired with standard regimens in patients who failed prior myeloma therapy.
A French trial investigated whether circulating immune cell profiles, specifically CD226 expression, could predict who responds to Atezolizumab/Bevacizumab in advanced HCC.
Modified immune cells engineered to overcome cancer's defenses completed safety testing in lymphoma patients.
Small trial tests innovative immune cell therapy for patients with relapsed non-Hodgkin's lymphoma who failed standard treatments.
A Phase 1/2 trial tests whether combining durvalumab, tremelimumab, and FOLFOX chemotherapy can safely boost immune response in mCRC.
A 10-week supervised strength program targets chronic inflammation and self-efficacy in long-term allogeneic HCT survivors.
A randomized Phase 2 trial investigates whether PD-1 inhibitor discontinuation after early response is safe in non-small cell lung cancer.
